A federal court preliminarily approved Acadia Pharmaceuticals’ proposed derivative settlement on August 24, 2026, with a settlement hearing scheduled for 2027. If approved, stockholders would be barred from contesting the settlement or pursuing released claims. The derivative action is not a class action and offers no common fund for monetary claims.

Key Highlights

  • The proposed resolution covers a derivative lawsuit and related Section 220 and litigation demands.
  • Nearly 4,000 pages of company books and records were obtained and reviewed during the related demands.
  • Acadia’s notice recounts share-price declines of more than 45% and 17% after separate regulatory disclosures.

ACADIA PHARMACEUTICALS INC (NASDAQ: ACAD) must notify stockholders about a proposed settlement in case 3:23-cv-02293 after a federal court granted preliminary approval on August 24, 2026. If approved, the resolution would affect holders’ rights to challenge the settlement and pursue released claims.

Proposed Derivative Settlement Terms

The proposed resolution covers the stockholder derivative action, related Section 220 demands and other litigation demands. Stockholders, Acadia as the nominal defendant and the individual defendants agreed to settlement terms in writing. Court approval would permanently prevent affected holders from contesting the settlement’s approval or pursuing claims covered by the release. The matter is not a class action.

2027 Hearing and Underlying Claims

Nearly 4,000 pages of books and records were obtained and reviewed in response to demands connected with the alleged wrongdoing. The notice describes claims brought on behalf of Acadia against individual directors and officers, including allegations involving Fiduciary duties, corporate assets, Insider Trading and securities-law provisions. It also recounts that Acadia’s share price fell more than 45% after a deficiency disclosure and dropped 17% after a later regulatory response concerning pimavanserin.